País: Cingapura
Língua: inglês
Origem: HSA (Health Sciences Authority)
NIFEDIPINE
BAYER (SOUTH EAST ASIA) PTE LTD
C08CA05
60 mg
TABLET, FILM COATED
NIFEDIPINE 60 mg
ORAL
Prescription Only
Bayer AG
ACTIVE
1996-09-04
Adalat LA PI_SG_CCDS16_ 27 Jun 2012 1 Instructions for use Please read carefully! Active ingredient: nifedipine Extended release tablets Coronary therapeutic/antihypertensive active ingredient nifedipine Extended release tablets PRESCRIPTION USE ONLY QUANTITATIVE COMPOSITION ADALAT LA 20 : 1 prolonged-release tablet contains 20 mg nifedipine ADALAT LA 30 : 1 prolonged-release tablet contains 30 mg nifedipine ADALAT LA 60 : 1 prolonged-release tablet contains 60 mg nifedipine PHARMACEUTICAL FORM Adalat LA 20: Round, convex prolonged-release tablet with pink coat, laser hole on one side and ADALAT20 on the other. Adalat LA 30: Round, convex prolonged-release tablet with pink coat, laser hole on one side and ADALAT30 on the other. Adalat LA 60: Round, convex prolonged-release tablet with pink coat, laser hole on one side and ADALAT60 on the other. PHARMACODYNAMIC PROPERTIES Nifedipine is a calcium antagonist of the 1,4-dihydropyridine type. Calcium antagonists reduce the transmembranal influx of calcium ions through the slow calcium channel into the cell. Nifedipine acts particularly on the cells of the myocardium and the smooth muscle cells of the coronary arteries and the peripheral resistance vessels. In the heart nifedipine dilates the coronary arteries, especially the large conductance vessels, even in the free wall segment of partially stenosed areas. Further, nifedipine reduces the vascular smooth muscle tone in the coronary arteries and prevents vasospasm. The end-result is an increased poststenotic blood flow and an increased oxygen supply. Parallel to this, nifedipine reduces the oxygen requirement by lowering p Leia o documento completo
Adalat LA PI_CCDS17_October 2017 1 INSTRUCTIONS FOR USE PLEASE READ CAREFULLY! ADALAT® LA ACTIVE INGREDIENT: NIFEDIPINE Coronary therapeutic/antihypertensive Extended release tablets PRESCRIPTION USE ONLY EXTENDED RELEASE TABLETS ACTIVE INGREDIENT NIFEDIPINE QUANTITATIVE COMPOSITION ADALAT LA 20 : 1 prolonged-release tablet contains 20 mg nifedipine ADALAT LA 30 : 1 prolonged-release tablet contains 30 mg nifedipine ADALAT LA 60 : 1 prolonged-release tablet contains 60 mg nifedipine PHARMACEUTICAL FORM Adalat LA 20: Round, convex prolonged-release tablet with pink coat, laser hole on one side and ADALAT20 on the other. Adalat LA 30: Round, convex prolonged-release tablet with pink coat, laser hole on one side and ADALAT30 on the other. Adalat LA 60: Round, convex prolonged-release tablet with pink coat, laser hole on one side and ADALAT60 on the other. PHARMACODYNAMIC PROPERTIES Nifedipine is a calcium antagonist of the 1,4-dihydropyridine type. Calcium antagonists reduce the transmembranal influx of calcium ions through the slow calcium channel into the cell. Nifedipine acts particularly on the cells of the myocardium and the smooth muscle cells of the coronary arteries and the peripheral resistance vessels. In the heart nifedipine dilates the coronary arteries, especially the large conductance vessels, even in the free wall segment of partially stenosed areas. Further, nifedipine reduces the vascular smooth muscle tone in the coronary arteries and prevents vasospasm. The end-result is an increased poststenotic blood flow and an increased oxygen supply. Parallel to this, nifedipine reduces the oxygen requirement by lowering peripheral resistance (afterload). With long-term use nifedipine can also prevent the development of new atherosclerotic lesions in the coronary arteries. Nifedipine reduces the smooth muscle tone of the arterioles, thus lowering the increased peripheral resistance and consequently the blood pressure. At the beginning of the nifedipine treatment there may be a transient reflex increase in he Leia o documento completo